PubMed:7524825 / 130-434 JSONTXT

{"project":"Glycan-Motif","denotations":[{"id":"T2","span":{"begin":18,"end":22},"obj":"https://glytoucan.org/Structures/Glycans/G00054MO"},{"id":"T3","span":{"begin":24,"end":30},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T4","span":{"begin":82,"end":88},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T5","span":{"begin":189,"end":193},"obj":"https://glytoucan.org/Structures/Glycans/G00054MO"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T2","span":{"begin":18,"end":22},"obj":"Glycan_Motif"},{"id":"T3","span":{"begin":24,"end":30},"obj":"Glycan_Motif"},{"id":"T4","span":{"begin":82,"end":88},"obj":"Glycan_Motif"},{"id":"T5","span":{"begin":189,"end":193},"obj":"Glycan_Motif"}],"attributes":[{"id":"A2","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00054MO"},{"id":"A3","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81533KY"},{"id":"A4","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81533KY"},{"id":"A5","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00054MO"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T2","span":{"begin":18,"end":22},"obj":"https://glytoucan.org/Structures/Glycans/G00054MO"},{"id":"T3","span":{"begin":24,"end":30},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T4","span":{"begin":82,"end":88},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T5","span":{"begin":189,"end":193},"obj":"https://glytoucan.org/Structures/Glycans/G00054MO"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T2","span":{"begin":0,"end":304},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":304},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":304},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T17","span":{"begin":205,"end":212},"obj":"FMAID:67257"},{"id":"_T18","span":{"begin":205,"end":212},"obj":"FMAID:165447"},{"id":"_T19","span":{"begin":219,"end":225},"obj":"FMAID:178661"},{"id":"_T20","span":{"begin":272,"end":277},"obj":"FMAID:169002"},{"id":"_T21","span":{"begin":272,"end":277},"obj":"FMAID:68646"},{"id":"_T22","span":{"begin":293,"end":303},"obj":"FMAID:62932"},{"id":"_T23","span":{"begin":293,"end":303},"obj":"FMAID:62933"},{"id":"_T24","span":{"begin":293,"end":303},"obj":"FMAID:62931"},{"id":"_T25","span":{"begin":293,"end":303},"obj":"FMAID:167265"},{"id":"_T26","span":{"begin":293,"end":303},"obj":"FMAID:167268"},{"id":"_T27","span":{"begin":293,"end":303},"obj":"FMAID:167267"},{"id":"_T28","span":{"begin":295,"end":303},"obj":"FMAID:165243"},{"id":"_T29","span":{"begin":295,"end":303},"obj":"FMAID:61795"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"uniprot-human","denotations":[{"id":"T2","span":{"begin":293,"end":303},"obj":"http://www.uniprot.org/uniprot/P16581"},{"id":"T7","span":{"begin":44,"end":50},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T8","span":{"begin":102,"end":108},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T10","span":{"begin":266,"end":268},"obj":"http://www.uniprot.org/uniprot/P11150"},{"id":"T11","span":{"begin":266,"end":268},"obj":"http://www.uniprot.org/uniprot/P35914"},{"id":"T12","span":{"begin":266,"end":268},"obj":"http://www.uniprot.org/uniprot/Q14469"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"uniprot-mouse","denotations":[{"id":"T2","span":{"begin":293,"end":303},"obj":"http://www.uniprot.org/uniprot/Q00690"},{"id":"T7","span":{"begin":266,"end":268},"obj":"http://www.uniprot.org/uniprot/P27656"},{"id":"T8","span":{"begin":266,"end":268},"obj":"http://www.uniprot.org/uniprot/P38060"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T2","span":{"begin":44,"end":48},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T3","span":{"begin":44,"end":48},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T4","span":{"begin":102,"end":106},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T5","span":{"begin":102,"end":106},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T6","span":{"begin":272,"end":277},"obj":"http://purl.bioontology.org/ontology/STY/T025"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GO-BP","denotations":[{"id":"T8","span":{"begin":140,"end":150},"obj":"http://purl.obolibrary.org/obo/GO_0000746"},{"id":"T11","span":{"begin":247,"end":262},"obj":"http://purl.obolibrary.org/obo/GO_0051100"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GO-MF","denotations":[{"id":"T2","span":{"begin":295,"end":303},"obj":"http://purl.obolibrary.org/obo/GO_0030246"},{"id":"T7","span":{"begin":255,"end":262},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T13","span":{"begin":255,"end":262},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T19","span":{"begin":255,"end":262},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T25","span":{"begin":255,"end":262},"obj":"http://purl.obolibrary.org/obo/GO_0005488"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GO-CC","denotations":[{"id":"T4","span":{"begin":272,"end":277},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"NGLY1-deficiency","denotations":[{"id":"PD-NGLY1-deficiency-B_T1","span":{"begin":68,"end":74},"obj":"chem:24139"}],"namespaces":[{"prefix":"hgnc","uri":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:"},{"prefix":"omim","uri":"https://www.omim.org/entry/"},{"prefix":"chem","uri":"https://pubchem.ncbi.nlm.nih.gov/compound/"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G76685HR\""},{"id":"GlycanIUPAC_T2","span":{"begin":82,"end":88},"obj":"\"http://rdf.glycoinfo.org/glycan/G76685HR\""},{"id":"GlycanIUPAC_T3","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G65881BF\""},{"id":"GlycanIUPAC_T4","span":{"begin":82,"end":88},"obj":"\"http://rdf.glycoinfo.org/glycan/G65881BF\""},{"id":"GlycanIUPAC_T5","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G82702MH\""},{"id":"GlycanIUPAC_T6","span":{"begin":82,"end":88},"obj":"\"http://rdf.glycoinfo.org/glycan/G82702MH\""},{"id":"GlycanIUPAC_T7","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G51494MY\""},{"id":"GlycanIUPAC_T8","span":{"begin":82,"end":88},"obj":"\"http://rdf.glycoinfo.org/glycan/G51494MY\""},{"id":"GlycanIUPAC_T9","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G37109XL\""},{"id":"GlycanIUPAC_T10","span":{"begin":82,"end":88},"obj":"\"http://rdf.glycoinfo.org/glycan/G37109XL\""},{"id":"GlycanIUPAC_T11","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G47427MX\""},{"id":"GlycanIUPAC_T12","span":{"begin":82,"end":88},"obj":"\"http://rdf.glycoinfo.org/glycan/G47427MX\""},{"id":"GlycanIUPAC_T13","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G89927NS\""},{"id":"GlycanIUPAC_T14","span":{"begin":82,"end":88},"obj":"\"http://rdf.glycoinfo.org/glycan/G89927NS\""},{"id":"GlycanIUPAC_T15","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G49112ZN\""},{"id":"GlycanIUPAC_T16","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G50059AJ\""},{"id":"GlycanIUPAC_T17","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G76218YK\""},{"id":"GlycanIUPAC_T18","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G50102KR\""},{"id":"GlycanIUPAC_T19","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G10717VS\""},{"id":"GlycanIUPAC_T20","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G60524RK\""},{"id":"GlycanIUPAC_T21","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G84407TT\""},{"id":"GlycanIUPAC_T22","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G64717JT\""},{"id":"GlycanIUPAC_T23","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G45003TT\""},{"id":"GlycanIUPAC_T24","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G73923FP\""},{"id":"GlycanIUPAC_T25","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G78231MB\""},{"id":"GlycanIUPAC_T26","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G80487UG\""},{"id":"GlycanIUPAC_T27","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G29758MI\""},{"id":"GlycanIUPAC_T28","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G02671KD\""},{"id":"GlycanIUPAC_T29","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G57926TZ\""},{"id":"GlycanIUPAC_T30","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G41718FD\""},{"id":"GlycanIUPAC_T31","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G99840FL\""},{"id":"GlycanIUPAC_T32","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G64321UX\""},{"id":"GlycanIUPAC_T33","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G11231EG\""},{"id":"GlycanIUPAC_T34","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G62741TN\""},{"id":"GlycanIUPAC_T35","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G51576ZQ\""},{"id":"GlycanIUPAC_T36","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G66056LD\""},{"id":"GlycanIUPAC_T37","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G02768BF\""},{"id":"GlycanIUPAC_T38","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G26168RO\""},{"id":"GlycanIUPAC_T39","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G42890HL\""},{"id":"GlycanIUPAC_T40","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G17533VU\""},{"id":"GlycanIUPAC_T41","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G34306RG\""},{"id":"GlycanIUPAC_T42","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G88735KU\""},{"id":"GlycanIUPAC_T43","span":{"begin":53,"end":56},"obj":"\"http://rdf.glycoinfo.org/glycan/G82605UA\""},{"id":"GlycanIUPAC_T44","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T45","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T46","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T47","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T48","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T49","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T50","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T51","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T52","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T53","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T54","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T55","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T56","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T57","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T58","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T59","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T60","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T61","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T62","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T63","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T64","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T65","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T66","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T67","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T68","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T69","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T70","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T71","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T72","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T73","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T74","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T75","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T76","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T77","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T78","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T79","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T80","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T81","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T82","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T83","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T84","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T85","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T86","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T87","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T88","span":{"begin":68,"end":74},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GlycoBiology-Motifs","denotations":[{"id":"T2","span":{"begin":18,"end":22},"obj":"http://rdf.glycoinfo.org/glycan/G00054MO"},{"id":"T3","span":{"begin":189,"end":193},"obj":"http://rdf.glycoinfo.org/glycan/G00054MO"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"Lectin","denotations":[{"id":"Lectin_T2","span":{"begin":295,"end":303},"obj":"https://acgg.asia/db/lfdb/LfDB0013"},{"id":"Lectin_T8","span":{"begin":293,"end":303},"obj":"https://acgg.asia/db/lfdb/LfDB0043"},{"id":"Lectin_T14","span":{"begin":295,"end":303},"obj":"https://acgg.asia/db/lfdb/LfDB0142"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"Glycan-GlyCosmos","denotations":[{"id":"T1","span":{"begin":24,"end":30},"obj":"Glycan"},{"id":"T2","span":{"begin":82,"end":88},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A3","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A4","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T2","span":{"begin":0,"end":304},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":304},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":304},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T2","span":{"begin":0,"end":304},"obj":"Sentence"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":24,"end":30},"obj":"Glycan"},{"id":"T2","span":{"begin":82,"end":88},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A3","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A4","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"}],"text":"Free, monovalent, SLeX (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc), SLn (Neu5Ac alpha 2-3Gal beta 1-4GlcNAc) and corresponding BSA-conjugated forms--displaying different ratios of SLeX and SLn to protein--were tested for their ability to inhibit binding of HL-60 cells to immobilized E-selectin."}